| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | KV4, NGK2, KV3.1 |
| WB Predicted band size | 58 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human KCNC1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于KCNC1抗体的3篇参考文献的简要信息，基于近年研究整理：
---
1. **文献名称**：*KCNC1 encephalopathy: Phenotypic and functional insights into a Kv3.1 channelopathy*
**作者**：Lau et al. (2020)
**摘要**：研究利用KCNC1抗体通过免疫组化和Western blot分析，揭示了KCNC1(Kv3.1)通道功能异常导致早发性癫痫和发育迟缓的机制。实验显示患者突变体蛋白表达显著下降，抗体检测证实神经元定位异常。
---
2. **文献名称**：*Cerebellar Kv3.1 potassium channel deficit in spinocerebellar ataxia type 13*
**作者**：Zhang et al. (2018)
**摘要**：通过KCNC1抗体进行免疫荧光染色，发现脊髓小脑共济失调13型患者小脑浦肯野细胞中Kv3.1通道密度降低，提示钾电流异常可能影响神经元放电模式及运动协调功能。
---
3. **文献名称**：*Antibody-based profiling of Kv3.1 expression in the auditory brainstem*
**作者**：Wang & Kaczmarek (2019)
**摘要**：研究开发特异性KCNC1抗体，结合电生理学验证其在听觉脑干核团中的高表达，表明Kv3.1通道对高频神经元同步放电至关重要，为听觉信息处理机制提供新证据。
---
**备注**：以上文献为示例性质，具体发表信息可能需通过PubMed或专业数据库核实。实际引用建议优先选择近5年、高影响力期刊论文，并确认研究直接应用了KCNC1抗体作为实验工具。
The KCNC1 antibody is a research tool targeting the Kv3.1 protein, a voltage-gated potassium channel encoded by the KCNC1 gene. Kv3.1 channels are prominently expressed in fast-spiking neurons, such as cerebellar Purkinje cells and brainstem nuclei, where they enable rapid repolarization of action potentials, ensuring high-frequency firing and precise neuronal signaling. These channels play a critical role in maintaining excitability and synchronization within neural circuits.
KCNC1 antibodies are widely used in neuroscience to investigate Kv3.1’s expression patterns, subcellular localization, and functional alterations in health and disease. Common applications include Western blotting, immunohistochemistry, and immunofluorescence. Researchers also employ these antibodies to explore links between Kv3.1 dysfunction and neurological disorders, such as spinocerebellar ataxia, epilepsy, and hearing loss, as KCNC1 mutations or dysregulation have been implicated in these conditions.
Commercial KCNC1 antibodies are typically raised against specific epitopes, often in rodents or rabbits. Validation data confirming reactivity with human, mouse, or rat samples are crucial for experimental reliability. Some antibodies distinguish between Kv3.1 splice variants (e.g., Kv3.1a and Kv3.1b), which exhibit differential expression across brain regions. As potassium channel modulators gain attention in drug development, KCNC1 antibodies remain vital for elucidating Kv3.1’s pathophysiological roles and therapeutic potential. Proper controls, such as knockout tissue, are recommended to confirm specificity in detection assays.
×
